Cardiology

Evacetrapib fails to reduce major adverse cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol ...

Cardiology

PCSK9 monoclonal antibodies show promise in ACS

(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

Cardiology

Newly identified genetic errors may prevent heart attacks

To reduce risk of heart attack, the benefits of a healthy lifestyle are clear. But genetics can still stack the deck. Some people's genes bestow a natural advantage—or disadvantage—in protecting against heart disease, ...

Medications

Evolocumab: No hint of added benefit

Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia. ...

page 11 from 17